Back to Search Start Over

Increased relative biological effectiveness and periventricular radiosensitivity in proton therapy of glioma patients

Authors :
Jan Eulitz
Esther G. C. Troost
Lauritz Klünder
Felix Raschke
Christian Hahn
Erik Schulz
Annekatrin Seidlitz
Justus Thiem
Caroline Karpowitz
Patricia Hahlbohm
Arne Grey
Kay Engellandt
Steffen Löck
Mechthild Krause
Armin Lühr
Source :
Radiotherapy and Oncology 178(2023), 109422
Publication Year :
2022

Abstract

Purpose Currently, there is an intense debate on variations in intra-cerebral radiosensitivity and relative biological effectiveness (RBE) in proton therapy of primary brain tumours. Here, both effects were retrospectively investigated using late radiation-induced brain injuries (RIBI) observed in follow-up after proton therapy of patients with diagnosed glioma. Methods In total, 42 WHO grade 2–3 glioma patients out of a consecutive patient cohort having received (adjuvant) proton radio(chemo)therapy between 2014 and 2017 were eligible for analysis. RIBI lesions (symptomatic or clinically asymptomatic) were diagnosed and delineated on contrast-enhanced T1-weighted magnetic resonance imaging scans obtained in the first two years of follow-up. Correlation of RIBI location and occurrence with dose (D), proton dose-averaged linear energy transfer (LET) and variable RBE dose parameters were tested in voxel- and in patient-wise logistic regression analyses. Additionally, anatomical and clinical parameters were considered. Model performance was estimated through cross-validated area-under-the-curve (AUC) values. Results In total, 64 RIBI lesions were diagnosed in 21 patients. The median time between start of proton radio(chemo)therapy and RIBI appearance was 10.2 months. Median distances of the RIBI volume centres to the cerebral ventricles and to the clinical target volume border were 2.1 mm and 1.3 mm, respectively. In voxel-wise regression, the multivariable model with D, D × LET and periventricular region (PVR) revealed the highest AUC of 0.90 (95 % confidence interval: 0.89–0.91) while the corresponding model without D × LET revealed a value of 0.84 (0.83–0.86). In patient-level analysis, the equivalent uniform dose (EUD11, a = 11) in the PVR using a variable RBE was the most prominent predictor for RIBI with an AUC of 0.63 (0.32–0.90). Conclusions In this glioma cohort, an increased radiosensitivity within the PVR was observed as well as a spatial correlation of RIBI with an increased RBE. Both need to be considered when delivering radio(chemo)therapy using proton beams.

Details

ISSN :
18790887
Volume :
178
Database :
OpenAIRE
Journal :
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Accession number :
edsair.doi.dedup.....a37a106bd9a2314b30a0140ae06609f9